CBD Has Not Yet Shown Clear Benefits for Alcohol Use Disorder in Human Trials

This was a narrative review, meaning the researchers brought together and assessed existing research rather than testing CBD in a new clinical trial. The review updates earlier summaries published in 2019, when there were few human studies of CBD for alcohol-related outcomes.

The news coverage reports that the reviewers assessed 29 newer studies, including 16 animal studies and nine human studies. The journal abstract does not provide a study-by-study breakdown, participant numbers, treatment lengths, or detailed outcome measures. That means this review can describe the overall direction of the evidence, but the supplied material does not allow a precise estimate of CBD’s effects in people.

In animals, the evidence was more encouraging. The review found strong preclinical evidence that CBD isolate, meaning CBD without other cannabis compounds, can reduce alcohol consumption. Animal studies also suggest CBD may ease signs linked to alcohol withdrawal and may lessen alcohol-related harm to the liver and nervous system. Findings on alcohol craving, reward, and motivation were mixed.

Animal research is useful for identifying ideas worth testing, but it cannot establish that a treatment works for people. Differences in biology, dose, timing, and how a drug is given can all affect whether results carry over from animal studies to human care.

In people, the picture was less promising. According to the review abstract, clinical trials have yielded largely null findings for CBD and alcohol use. Evidence on craving and alcohol reward has been inconsistent. The authors also say there is limited clinical evidence on whether CBD could help with alcohol-related liver disease, withdrawal symptoms, or neurodegeneration, which refers to damage or loss of nerve cells.

The gap between animal and human findings may partly reflect how CBD is used. The review notes that CBD taken by mouth has poor bioavailability. In everyday terms, only a limited and variable amount may reach the bloodstream. Different formulations or routes of administration might change that, but this remains a question for research, not an established solution.

The review also highlights early observational findings involving plant-derived CBD products that included small amounts of THC and other cannabinoids. THC is the cannabis compound that can cause intoxication. These studies suggested that such formulations might reduce alcohol use and craving. However, observational studies track what happens in real-world settings; they do not randomly assign treatments. As a result, they cannot show that the product itself caused any reported change.

The authors say this question should be tested in a randomized, controlled trial. In that kind of study, people are assigned by chance to different groups, which can help separate a treatment’s effects from expectations, differences between participants, and other influences.

Future trials should clearly report the amounts of CBD, THC, and other cannabinoids used. The researchers also recommend measuring CBD levels in participants’ blood. They suggest that “biobehavioral phenotyping,” or grouping people by measurable biological and behavioral characteristics, could help identify whether certain subgroups are more likely to benefit.

For now, the review’s central message is cautious: CBD remains a research possibility for alcohol use disorder, but it has not demonstrated clear effectiveness in human clinical trials. Stronger studies are needed before its role in treatment can be understood.